Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Tuesday is the final day of Sexually Transmitted Disease Awareness Month, and the state CDC says it's recommending prevention, screening and treatment. The agency says Maine has seen "dramatic increases" in gonorrhea and syphilis in the last five years. Gonorrhea cases increased nearly 200 percent, to 686, from 2014 to 2018. Syphilis cases have risen by almost 600 percent, to 104, in that same timeframe. Acting Maine CDC Director Nancy Beardsley says the health consequences of sexually transmitted infections are serious enough that residents "know the facts about STDs and get tested if they believe they are at risk." Claim: Maine stresses test as sexually transmitted infections surge.

Output: The Maine Center for Disease Control and Prevention is calling on residents to get tested for sexually transmitted infections amid a spike in cases of gonorrhea and syphilis in the state.

Input: Consider Input: Paragraph: There was no discussion of costs. Costs would include treating the double digit rates of incontinence and erectile dysfunction in these younger men who do have surgery. The surgery may help them live longer, but many, especially since younger at time of surgery, live decades with these potential harms and folllowup costs of the surgical choice. This should get at least a line in such stories. While describing some of the differences observed in general terms without quantification, the story provided absolute percentage of men dying from prostate cancer in the two study groups. The story then went on to explain that the difference was in the men who were less 65 years of age at the time of diagnosis. The story would have been better if it had more clearly explained this important caveat about the benefit seen. The potential harms associated with various approaches to treating prostate cancer as well as the increased risk of prostate cancer progression and death seen in the cohort of men who followed the watchful waiting approach were discussed. The story did a laudable job of providing information about the study reported on including the fact that the results most recently published basically expand the timeframe of followup on these men which have previously been published. It provided insight about the number of men involved in the study, how their prostate cancer was detected and that the men had been randomly assigned to their treatment group. The story did not engage in overt disease mongering. Two clinicians who were not involved in the study provided quotes which were used in the story. The story included a list of the commonly available treatment options for early stage prostate cancer. But we must give an unsatisfactory score because the story included a factually incorrect statement indicating that watchful waiting is synonymous with active surveillance. It is not. The story went on to misinform readers by indicating "watchful waiting is often recommended when a man is not expected to die of the cancer" by failing to complete the thought by explaining that the reason they are not expected to die of the cancer is because their advanced age makes it unlikely that the cancer will have sufficient time to progress to lethality OR because they have other diseases from which they are likely to succumb before there is time for the prostate cancer to be deadly. An important caveat about how the prostate cancer in the study differed from the way in which prostate cancer is most commonly detected today in the US was explained. The story provided a reasonable view of the novelty of the treatment options detailed in the study along with the critically important caveat that the majority of the men in the study had their prostate cancer first detected at a later state than is seen with the current screening practices in the US. The story did not rely on a news release. Claim: Aggressive Treatment May Be Beneficial for Early Prostate Cancer

Output: As with the NPR and AP stories we also reviewed, this story helped frame this issue in the first few lines rather than burying it at the end as so often is the case. To have an expert not involved in study quoted in the second paragraph saying "findings are not likely to be practice-changing" provides readers with balanced perspective right from the start. It was also good that the story concluded with a quote that expanded on what it means to "individualize" treatment. Unlike the concluding quote in the NPR story, this one provided language suggestive of shared decision making by adding 'in relation to the risk stratification of disease, PATIENT DESIRES, health status, and RISK TOLERANCE". (emphasis added) Good way to end the story. Decisions about what, if anything, to do when facing a diagnosis of early stage prostate cancer is difficult and this story provided readers with useful information to consider.

Input: Consider Input: Paragraph: The public-private partnership includes the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation and the World Bank, among others. The funding announcement was made after a meeting of GAVI's board. GAVI said the investment, which it called an estimate, will be provided between now and 2025. Since the current outbreak in eastern Congo was identified last August, health officials have immunized more than 255,000 people with a recently licensed vaccine made by Merck. To date there have been nearly 3,200 confirmed Ebola cases, including more than 2,200 deaths, in what has become the second deadliest Ebola outbreak in history. Dr. Ngozi Okonjo-Iweala, chair of Gavi's board, called the creation of the Ebola vaccine stockpile a "historic milestone in humanity's fight against this horrific disease." GAVI said "a coordinating mechanism" to decide how and when vaccines will be used will be established with partner organizations. There are similar stockpiles for vaccines against yellow fever, meningitis and cholera. Those limited shots are doled out to developing countries by WHO, UNICEF, the Red Cross and Doctors Without Borders after receiving technical advice from others. The Ebola vaccine stockpile will be available to all countries, but only developing countries will be able to get vaccines for free in addition to support for the logistical costs of mounting vaccination campaigns. Jason Nickerson, a humanitarian affairs adviser at Doctors Without Borders, said the new stockpile would change how officials respond to future Ebola outbreaks. "Knowing how many doses of the vaccine exist in the world, and then being able to get a supply of them to high-risk countries in a very quick way, gives us another tool to respond to these outbreaks," he said. Earlier this year, the medical charity publicly called for an independent committee to oversee Ebola vaccination efforts in Congo, saying WHO sometimes used arbitrary criteria to determine who would get immunized. It said the fact that Ebola was continuing to spread despite the large number of people vaccinated was a damning assessment of the response. Containing this outbreak has been complicated by violence and misunderstandings in a part of Congo that had never reported an Ebola case before. Last week, response activities were suspended after attacks killed four Ebola responders, including a member of a vaccination team. Multiple rebel groups operate in eastern Congo and the region has been described as a war zone. WHO has warned continued attacks on health workers and Ebola clinics could undermine attempts to curb Ebola and prompt a resurgence of the disease. Claim: Vaccine group announces creation of Ebola vaccine stockpile.
Output: The vaccine alliance GAVI announced Thursday it would invest $178 million to create a global stockpile of about 500,000 Ebola vaccines, a decision that health officials say could help prevent future outbreaks from spiraling out of control.